American Society of Hirudotherapy

Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review

Systematic review published in Journal of intensive care medicine (2016)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Systematic reviewDrug DevelopmentSanfilippo F et al. · Journal of intensive care medicine, 2017

Abstract

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) offers therapeutic options in refractory respiratory and/or cardiac failure. Systemic anticoagulation with heparin is routinely administered. However, in patients with heparin-induced thrombocytopenia or heparin resistance, the direct thrombin inhibitor bivalirudin is a valid option and has been increasingly used for ECMO anticoagulation. We aimed at evaluating its safety and its optimal dosing for ECMO. METHODS: Systematic web-based literature search of PubMed and EMBASE performed via National Health Service Library Evidence and manually, updated until January 30, 2016. RESULTS: The search revealed 8 publications relevant to the topic (5 case reports). In total, 58 patients (24 pediatrics) were reported (18 received heparin as control groups). Bivalirudin was used with or without loading dose, followed by infusion at different ranges (lowest 0.1-0.2 mg/kg/h without loading dose; highest 0.5 mg/kg/h after loading dose). The strategies for monitoring anticoagulation and optimal targets were dissimilar (activated partial thromboplastin time 45-60 seconds to 42-88 seconds; activated clotting time 180-200 seconds to 200-220 seconds; thromboelastography in 1 study). CONCLUSION: Bivalirudin loading dose was not always used; infusion range and anticoagulation targets were different. In this systematic review, we discuss the reasons for this variability. Larger studies are needed to establish the optimal approach with the use of bivalirudin for ECMO.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleSystematic Review
Indexed MeSH termsAdultAnticoagulantsAntithrombinsChildExtracorporeal Membrane OxygenationHeart FailureHirudinsHumansPeptide FragmentsRecombinant ProteinsRespiratory InsufficiencyThrombocytopeniaThrombolytic Therapy

Summary

A systematic review of 8 publications on bivalirudin for ECMO anticoagulation, covering 58 patients (24 pediatric), found dosing, use of a loading dose, and monitoring targets highly variable, and larger studies are needed.

Why This Matters for Hirudotherapy

This systematic review evaluated the safety and optimal dosing of bivalirudin—a direct thrombin inhibitor per the abstract—as an alternative anticoagulant for extracorporeal membrane oxygenation in patients with heparin-induced thrombocytopenia or heparin resistance. Analyzing 8 publications encompassing 58 patients, the authors found considerable variability in loading dose use, infusion ranges, and anticoagulation monitoring targets across centers. The review is limited by the underlying evidence base, which was predominantly case reports, and the authors conclude that larger studies are needed to establish the optimal approach. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Sanfilippo F, Asmussen S, Maybauer DM, Santonocito C, Fraser JF, Erdoes G, et al. Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review. J Intensive Care Med. 2017;32(5):312-319. doi:10.1177/0885066616656333. PMID: 27356945

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.